BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25942065)

  • 1. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
    Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
    J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
    Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
    Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
    Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
    Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
    Spandau U
    Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
    Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
    Goldman DR; Baumal CR
    J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
    Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
    Dorta P; Kychenthal A
    Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

  • 12. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab.
    Tseng CC; Chen SN; Hwang JF; Lin CJ
    J Pediatr Ophthalmol Strabismus; 2012 Aug; 49 Online():e41-3. PubMed ID: 22881829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
    Flavahan PW; Lavy TE; Wykes W
    Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of retinopathy of prematurity after bevacizumab injection.
    Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R
    Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
    Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
    Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
    [No Abstract]   [Full Text] [Related]  

  • 17. Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes.
    Mintz-Hittner HA
    J AAPOS; 2016 Dec; 20(6):478-480. PubMed ID: 27816750
    [No Abstract]   [Full Text] [Related]  

  • 18. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Mintz-Hittner HA; Kuffel RR
    Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use of bevacizumab in retinopathy of prematurity.
    Rishi E; Rishi P; Ratra D; Bhende M
    Retina; 2009 Feb; 29(2):284; author reply 284-5. PubMed ID: 18854784
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.